Latest News

• share
• favorite_border

• share
• favorite_border

LA JOLLA, CA—La Jolla Institute for Immunology (LJI) Professor Sujan Shresta, Ph.D., is on hand to share her expertise on dengue fever and dengue vaccine development. She is available to comment on urgent dengue virus research amidst the news of San Diego’s first locally acquired dengue virus case. LJI Professor Sujan Shresta, Ph.

• share
• favorite_border

The new study, led by researchers in the Saphire Lab at LJI, reveals the inner workings of the Ebola virus nucleocapsid. LA JOLLA, CA—At this moment, the world has few tools to combat deadly filoviruses, such as Ebola and Marburg viruses. The only approved vaccine and antibody treatments protect against just one filovirus species.

• share
• favorite_border

The LJI team uncovered important similarities between H5N1 and these common viruses, which allowed them to predict that many people already have "cross-reactive" T cells that are ready to target H5N1—should it ever mutate to cause widespread disease in humans.

• share
• favorite_border

La Jolla Institute for Immunology (LJI) has been selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).

• share
• favorite_border

Scientists at La Jolla Institute for Immunology (LJI) are investigating how the mutated clade 1 mpox virus may affect children and older patients—and how new vaccines can help the body fight back.

• share
• favorite_border

• share
• favorite_border

"As an infectious diseases clinician, I've always been focused on research into pathogen-host interactions. We need to know why some people get sicker than others."

• share
• favorite_border

The researchers hope to one day target this T cell population via drug therapy. "These cells may be a very important target for treating ulcerative colitis and perhaps other autoimmune diseases..."

• share
• favorite_border

LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) have developed a new computational method for linking molecular marks on our DNA to gene activity. Their work may help researchers connect genes to the molecular “switches” that turn them on or off. This research, published in Genome Biology, is an important step toward harnessing machine learning approaches to better understand links between gene expression and disease development.

• share
• favorite_border

Repeated vaccination and infection leads T cells and B cells to build an "immunity wall"

• share
• favorite_border

“Alison’s research has been very, very impactful, and her efforts have catalyzed a cultural exchange between the United State and Italy."

• share
• favorite_border

This method is a major leap forward for scientists investigating how proteins do their jobs in the immune system. “This method basically creates an entire new kind of world of experiments that people can do..."

• share
• favorite_border

The Institute's Flow Cytometry Core, which provides cutting-edge research services, has been named a BD Biosciences "Center of Excellence." Along with this distinction, the LJI Flow Core has brought in a sophisticated instrument for immune cell research: the BD FACSDiscover™ S8 Cell Sorter.

• share
• favorite_border

“We are hoping to use this competition not just as a way to examine the capacity of people to predict vaccination outcomes, but also as a way to address an important public health question,” says Peters.

• share
• favorite_border

Cancer researcher Miguel Reina-Campos, Ph.D., has joined the faculty of La Jolla Institute for Immunology (LJI) as an Assistant Professor to lead the Laboratory of Tissue Immune Networks. His laboratory at LJI aims to investigate the basis of CD8+ T cell tissue immunity to improve life-saving cancer immunotherapies.

• share
• favorite_border

Scientists at La Jolla Institute for Immunology (LJI) have uncovered important clues to how human T cells combat the bacterium that causes tuberculosis.

• share
• favorite_border

“We found sort of a special ‘flavor’ of CD4+ T cells critical for clearing this chronic virus replication,”

• share
• favorite_border

"These patients may be candidates in whom immunotherapy has the potential to show clinical benefit."

• share
• favorite_border

According to new predictions by La Jolla Institute for Immunology (LJI) researchers, if the new SARS-CoV-2 Pirola variant wants to evade T cells, it isn't doing a very good job.